Śpiewak, Mateusz http://orcid.org/0000-0002-2393-4194
Kłopotowski, Mariusz
Ojrzyńska, Natalia
Petryka-Mazurkiewicz, Joanna
Miłosz-Wieczorek, Barbara
Mazurkiewicz, Łukasz
Grzybowski, Jacek
Bilińska, Zofia
Witkowski, Adam
Marczak, Magdalena
Funding for this research was provided by:
Ministerstwo Nauki i Szkolnictwa Wyższego (IP 2014 0477 73)
National Institute of Cardiology (4.5/V/17)
Article History
Received: 29 May 2020
Revised: 3 July 2020
Accepted: 19 August 2020
First Online: 2 September 2020
Compliance with ethical standards
:
: The scientific guarantor of this publication is Mateusz Śpiewak.
: The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.
: One of the authors has significant statistical expertise. No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all subjects (patients) included prospectively in this study. Written informed consent for retrospective analysis was waived by the Institutional Review Board.
: Approval was granted by the local ethics committee of the National Institute of Cardiology, Warsaw, Poland (Reference number: 1656).
: Some study subjects or cohorts have been previously reported. The current analysis encompasses all patients with HCM who underwent cardiac MRI at our centre, thus including selected data that had been previously analysed in studies with smaller samples (Śpiewak et al <i>Eur J Radiol</i> 2010; Śpiewak et al <i>Int J Cardiovasc Imaging</i> 2010; Śpiewak et al <i>Kardiol Pol</i> 2010; Dąbrowski et al <i>Kardiol Pol</i> 2012; Małek et al <i>Magn Reson Imaging</i> 2015; Kłopotowski et al <i>J Cardiol</i> 2016; Mazurkiewicz et al <i>Clin Radiol</i> 2017; Gawor et al <i>Kardiol Pol</i> 2017; Śpiewak et al <i>J Cardiovasc Magn Reson</i> 2017; Gawor et al <i>Biomarkers</i> 2018; Dąbrowski et al <i>Kardiol Pol</i> 2019). The current analysis does not duplicate the results from previous studies. This manuscript differs substantially from our recent reports as follows: (1) the previous studies addressed different issues in patients with HCM (e.g. methods of late gadolinium enhancement quantification discrepancies between left ventricular mass and maximal wall thickness, the prognostic value of late gadolinium enhancement, the relation between late gadolinium enhancement and selected serum biomarkers, the value of native T1 mapping in patients with HCM and changes following alcohol septal ablation), and (2) the current study included a much larger population (<i>n</i> = 1006).
: • retrospective• observational• performed at one institution